|
業務類別
|
-- |
|
業務概覽
|
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types. |
| 公司地址
| 60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire, GBR, OX14 4RY |
| 電話號碼
| +44 1235430000 |
| 傳真號碼
| +44 1235430001 |
| 公司網頁
| https://www.adaptimmune.com |
| 員工數量
| 506 |
| Mr. William C. Bertrand, Esq.,Jr |
Chief Operating Officer |
美元 486.91K |
17/11/2025 |
| Mr. Christopher James Hill |
Director, Chief Executive Officer and Chief Financial Officer |
-- |
17/11/2025 |
|
|
| Mr. Christopher James Hill |
Director, Chief Executive Officer and Chief Financial Officer |
17/11/2025 |
| Dr. Garry E. Menzel, PhD |
Independent Director |
17/11/2025 |
| Mr. Lawrence M. Alleva |
Chairman of the Board |
17/11/2025 |
|
|
|
|
